JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase

NCT04943952 | Unknown

• 1 other identifier: JZP458-701-01
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study is an Expanded Access Protocol (EAP) of JZP458 in participants with ALL/LBL who are hypersensitive to an E.coli-derived asparaginase (allergic reaction or silent inactivation) and unable to access alternative licensed treatment, to receive JZP458 treatment prior to potential Food and Drug Administration (FDA) approval and commercial availability.

Conditions

Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma

Keywords

JZP458; Asparaginase Erwinia Chrysanthemi (Recombinant); Recombinant Erwinia Asparaginase; RC-P

Interventions

Asparaginase Erwinia Chrysanthemi (recombinant) DRUG

Participants will receive JZP458 via intramuscular injection.

Also known as: JZP458, RC-P

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient (or parent/legally authorized representative thereof) is able to understand and voluntarily give informed consent/assent
• Patient has a diagnosis of ALL or LBL
• Patient received appropriate standard treatment without success (or no standard treatment exists for the patient's condition), and no satisfactory alternative drug is available
• Patient had a ≥ Grade 2 allergic reaction (Common Terminology Criteria for Adverse Events \[CTCAE\] v5.0) to a long-acting E. coli-derived asparaginase OR have silent inactivation
• Patient, in Investigators' opinion, has fully recovered from their prior allergic reaction to E. coli-derived asparaginase Note: Patients must have completed antihistamine, epinephrine, and/or corticosteroid treatment for the allergic reaction ≥ 24 hours prior to JZP458 administration.
• Patient has adequate liver function, defined as: direct (conjugated) bilirubin ≤ 3X upper limit of normal (ULN); serum glutamic pyruvic transaminase (SGPT)(alanine aminotransferase \[ALT\]), and serum glutamic-oxaloacetic transaminase (SGOT)(aspartate transaminase \[AST\]) ≤ 5X ULN
• For female patients of childbearing potential (i.e., fertile, following menarche) and male patients who have female partners of childbearing potential:
• Patient has agreed to use medically acceptable methods of contraception with their partners for the duration of treatment with JZP458 and for 30 days after the last dose of JZP458.
• Medically acceptable methods of contraception that the patient may use include abstinence, progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action; a combination of male condoms with either cap, diaphragm, or sponge with spermicide (double barrier methods).

You may not qualify if:

• Patient is currently taking part in or is eligible for a clinical trial for JZP458
• Patient previously received asparaginase Erwinia Chrysanthemi AND has access to a short-acting non-E. Coliasparaginase
• Patient experienced concern of a possible adverse event (AE) related to asparaginase Erwinia Chrysanthemi
• Patient to receive asparaginase Erwinia Chrysanthemi within 1 week of plans to start JZP458
• Patient is concurrently receiving another investigational agent and/or treated with an investigational device at the same time as JZP458(within 48 hours)
• Patient has a history of ≥ Grade 3 pancreatitis (per CTCAE v5.0)
• Patient has a history of ≥ Grade 3 hypersensitivity to asparaginase Erwinia Chrysanthemi
• Patient has a prior history of asparaginase-associated ≥ Grade 3 (per CTCAE v5.0) haemorrhagic event or asparaginase-associated thrombus requiring anticoagulation therapy, excluding catheter-related thrombotic events
• Female patients who are lactating and do not agree to stop breast-feeding
• Eligibility Criteria (Re-Supply Requests)
• Patient continues to benefit from treatment with JZP458
• Patient has not encountered unacceptable toxicity
• Patient has not shown signs/symptoms of relapsed or refractory disease
• Patient has not encountered ≥ Grade 3hypersensitivity symptoms
• Patient is not pregnant or breastfeeding

Sponsors & Collaborators

• Jazz Pharmaceuticals: lead

MeSH Terms

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions

asparaginase erwinia chrysanthemi recombinant

Condition Hierarchy (Ancestors)

Leukemia, Lymphoid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 21, 2021
• First Posted: June 29, 2021
• Last Updated: August 3, 2021

Record last verified: 2021-07